Sign In
Buy RYTM
$84.71
+0.360 (+0.427%)
At Close: Jun 03, 2026
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
04:01pm, Tuesday, 08'th Oct 2024
BOSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neur
Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck
07:36am, Sunday, 22'nd Sep 2024
IMCIVREE is FDA-approved for obesity due to genetic mutations and aims to expand its label to include children as young as 2 years old. The company is also exploring IMCIVREE for hypothalamic obesity
Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 7.4% Jump Turn into More Strength?
11:50am, Wednesday, 18'th Sep 2024
Rhythm Pharmaceuticals (RYTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
04:01pm, Monday, 16'th Sep 2024
BOSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neu
Four Biotech Stocks Rally Toward Buy Points As Funds Load Up
01:31pm, Friday, 06'th Sep 2024
Biotech stocks have been rallying as funds load up. Five stocks have been outperforming the vast majority in the IBD database.
Rhythm Stock Up as FDA Accepts Obesity Drug sNDA for Younger Kids
11:35am, Tuesday, 27'th Aug 2024
RYTM gains 8% as FDA accepts Imcivree sNDA seeking label expansion of the drug to treat obesity in kids as young as two years old.
-- Label expansion sought to treat younger children with Bardet-Biedl syndrome or POMC/LEPR deficiency -- -- FDA sets PDUFA goal date of December 26, 2024 --
Three Biotech Stocks to Buy for the "Golden Age of Medicine"
01:49pm, Monday, 19'th Aug 2024
A year ago, medical experts and Nobel Laureates interviewed by The New York Times proclaimed "a Golden Age of Medicine" is here.
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
04:01pm, Tuesday, 13'th Aug 2024
BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families liv
Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2024 Earnings Call Transcript
11:22am, Tuesday, 06'th Aug 2024
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q2 2024 Earnings Conference Call August 6, 2024 8:00 AM ET Company Participants David Connolly - IR & Corporate Communications David Meeker - Chairman, CEO
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
09:16am, Tuesday, 06'th Aug 2024
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.82 per share a year ago.
Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update
07:00am, Tuesday, 06'th Aug 2024
-- Second quarter 2024 net revenue from global sales of IMCIVREE ® (setmelanotide) of $29.1 million -- -- Dosed first patients in supplemental, 12-patient Japanese cohort in global Phase 3 trial eval
IMCIVREE now authorized as treatment of obesity and control of hunger in adult patients and pediatric patients 2 years old or older with Bardet Biedl syndrome or POMC, PCSK1, or LEPR deficiency IMCIVR
Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
07:30am, Tuesday, 23'rd Jul 2024
BOSTON, July 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families liv
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
04:01pm, Thursday, 11'th Jul 2024
BOSTON, July 11, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families liv
